ArticleCytokine2008
Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity.
Article in Cytokine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 159 citations in OpenAlex.
- Effects of colchicine on lipolysis and adipose tissue inflammation in adults with obesity and metabolic syndrome.Obesity (Silver Spring, Md.) · 2022Trial
- Impact of rye-based evening meals on cognitive functions, mood and cardiometabolic risk factors: a randomized controlled study in healthy middle-aged subjects.Nutrition journal · 2018Trial
- Disulfiram Protects Against Diet-Induced Obesity by Reprogramming Systemic Lipid Partitioning Independent of GSDMD.bioRxiv : the preprint server for biology · 2026Article
- Adipose tissue releases nucleosides.American journal of physiology. Cell physiology · 2026Article
- Effects of Intraperitoneal Colchicine on the Metabolic Consequences of High Fat Diet-Induced Obesity in Mice.Endocrine, metabolic & immune disorders drug targets · 2026Article
- Iron-Inflammasome Crosstalk in Adipose Tissue: Unresolved Roles of NLRP3 and IL-1β in Metabolic Inflammation.International journal of molecular sciences · 2025Review
- Immunometabolic Interactions in Obesity: Implications for Therapeutic Strategies.Biomedicines · 2025Review
- Macrophages: friend or foe in diabetes pathogenesis and therapy.Frontiers in immunology · 2025Review
- The Interplay between Obesity and Inflammation.Life (Basel, Switzerland) · 2024Review
- IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells.Blood advances · 2024Article
- Impact of Lipids on Insulin Resistance: Insights from Human and Animal Studies.Drug design, development and therapy · 2024Review
- Review
- Article
- Cell death and inflammation during obesity: "Know my methods, WAT(son)".Cell death and differentiation · 2023Review
- Molecular tracking of insulin resistance and inflammation development on visceral adipose tissue.Frontiers in immunology · 2023Article
- Review
- Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm.Nature communications · 2022Article
- Antipsychotic-induced weight gain and metabolic effects show diurnal dependence and are reversible with time restricted feeding.Schizophrenia (Heidelberg, Germany) · 2022Article
- Triggering receptor expressed on myeloid cells-1 deletion in mice attenuates high-fat diet-induced obesity.Frontiers in endocrinology · 2022Article
- Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
The proinflammatory cytokine Interleukin 1 beta (IL-1beta) is elevated in obese individuals and rodents and it is implicated in impaired insulin secretion, decreased cell proliferation and apoptosis of pancreatic beta cells. In this study we describe the therapeutic effects by an IL-1beta antibody to improve glucose control in hyperglycemic mice with diet-induced obesity. After 13 weeks of treatment the IL-1beta antibody treated group showed reduced glycated hemoglobin (( *)P=0.049), reduced serum levels of proinsulin (( *)P=0.015), reduced levels of insulin and smaller islet size (( *)P=1.65E-13) relative to the control antibody treated group. Neutralization of IL-1beta also significantly reduced serum amyloid A (SAA) which is an indicator of inflammation-induced acute phase response (( *)P=0.024). While there was no improvement of obesity, a significant improvement of glycemic control and of beta cell function is achieved by this pharmacological treatment which may slow/prevent disease progression in Type 2 Diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.